Drug Profile
Research programme: therapeutics - Amgen/Carmot Therapeutics
Latest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Amgen; Carmot Therapeutics
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease; Unspecified
Most Recent Events
- 29 Jan 2024 Carmot Therapeutics has been acquired by Roche
- 28 Sep 2023 No recent reports of development identified for preclinical development in Unspecified in USA
- 01 Aug 2019 Preclinical trials in Unspecified in USA before August 2019 (Carmot Therapeutics pipeline, August 2019)